US FDA to Review Heart Risks of Novartis Corporation’s Parkinson’s Drug

WASHINGTON Aug 20 (Reuters) - The U.S. Food and Drug Administration said on Friday it will examine the potential heart risks of Novartis AG’s (NOVN.VX) Parkinson’s drug Stalevo, a combination of two treatments for the debilitating brain disease.